ライフサイエンスコーパス: peripheral artery

1 e primary sensor of intraluminal pressure in peripheral arteries.

2 sorption and distribution in cadaveric human peripheral arteries.

3 older age and occur similarly in central and peripheral arteries.

4 to atheromatous plaques in carotid or other peripheral arteries.

5 an important cardiovascular disorder of the peripheral arteries.

6 creased mortality, as has been suggested for peripheral arteries.

7 tly increased calcification in the aorta and peripheral arteries.

8 diabetes, we evaluated the role of CEPT1 in peripheral arteries and PPARalpha phosphorylation (Ser12

9 ad polyvascular disease in 3 beds (coronary, peripheral artery, cerebrovascular).

10 e (0.91, 0.82-1.01), and a 32% lower risk of peripheral artery disease (0.68, 0.60-0.78).

11 chronic kidney disease (1.7 [1.7-1.8]), and peripheral artery disease (2.3 [2.3-2.4]).

12 ), persistent or recurrent manifestations of peripheral artery disease (22.2%), cardiac conditions (1

13 tes (41.0%), moderate renal failure (40.2%), peripheral artery disease (33.7%), current smoker (13.8%

14 hypertrophy, LV ejection fraction <50%, and peripheral artery disease (ankle-brachial index, <0.90).

15 ratio, 1.20 [95% CI, 1.05-1.36; P=0.007) and peripheral artery disease (hazard ratio, 1.15 [95% CI, 1

16 ER = $44,779/QALY gained), and patients with peripheral artery disease (ICER = $13,427/QALY gained).

17 d dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation wit

18 diameter is associated with lower-extremity peripheral artery disease (LE-PAD).

19 Patients with qualifying peripheral artery disease (n=3787) had a history of clau

20 ARAS was associated with peripheral artery disease (p = 0.004) and lower high-den

21 than in controls without clinically evident peripheral artery disease (P<0.0001).

22 nto categories of 0-, 1-, 2-, 3- or 4-vessel peripheral artery disease (PAD) (ABI of <=0.9).

23 67, 95% CI, 1.14-2.46, P value = 0.008), and peripheral artery disease (PAD) (OR = 2.35, 95% CI, 1.38

24 cco use is an important preventable cause of peripheral artery disease (PAD) and a major determinant

25 about the prevalence of objectively assessed peripheral artery disease (PAD) and its clinical relevan

26 ssociated with chronic kidney disease (CKD), peripheral artery disease (PAD) and neuropathy.

27 Patients with peripheral artery disease (PAD) are at heightened risk f

28 Patients with peripheral artery disease (PAD) are at heightened risk o

29 Patients with peripheral artery disease (PAD) are at heightened risk o

30 Patients with peripheral artery disease (PAD) are at heightened risk o

31 Patients with peripheral artery disease (PAD) are at risk of major adv

32 New data on the epidemiology of peripheral artery disease (PAD) are available, and they

33 lking ability in people with lower extremity peripheral artery disease (PAD) are unclear.

34 cy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on

35 Lower extremity peripheral artery disease (PAD) burden differs by race/e

36 The prevalence of peripheral artery disease (PAD) continues to increase wo

37 with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromb

38 Peripheral artery disease (PAD) generates tissue ischemi

39 Patients with peripheral artery disease (PAD) have a higher risk of ma

40 Patients with lower-extremity peripheral artery disease (PAD) have greater functional

41 Patients with peripheral artery disease (PAD) have greater incidence o

42 Many patients with peripheral artery disease (PAD) have walking impairment

43 eases related to impaired blood flow such as peripheral artery disease (PAD) impact nearly 10 million

44 To define how the incidence of peripheral artery disease (PAD) in chronic kidney diseas

45 mine whether there is a higher prevalence of peripheral artery disease (PAD) in individuals with lowe

46 se and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States.

47 Peripheral artery disease (PAD) is a leading cause of ca

48 Peripheral artery disease (PAD) is associated with heigh

49 Peripheral artery disease (PAD) is associated with incre

50 Peripheral artery disease (PAD) is associated with incre

51 Peripheral artery disease (PAD) is associated with incre

52 Lower extremity peripheral artery disease (PAD) is frequently underdiagn

53 Peripheral artery disease (PAD) is underrecognized, unde

54 reely perfused and ligated femoral arteries: peripheral artery disease (PAD) model.

55 t for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent re

56 ysis patients, but its effect on the risk of peripheral artery disease (PAD) remains unclear.

57 Patients with peripheral artery disease (PAD) show an exaggerated EPR,

58 t evidence to support advising patients with peripheral artery disease (PAD) to participate in a home

59 shown by limb osteoporosis in patients with peripheral artery disease (PAD), but also could result f

60 variance) to estimate prevalence ratios for peripheral artery disease (PAD), coronary artery calcifi

61 Muscle ischemia, associated with peripheral artery disease (PAD), leads to the release of

62 le of nutrition in the primary prevention of peripheral artery disease (PAD), the third leading cause

63 er Medicaid Expansion (ME) for patients with peripheral artery disease (PAD).

64 r challenge to intraluminal drug delivery in peripheral artery disease (PAD).

65 e 6-minute walk performance in patients with peripheral artery disease (PAD).

66 d improving outcomes in patients with severe peripheral artery disease (PAD).

67 sed revascularization rates in patients with peripheral artery disease (PAD).

68 effective treatment option for patients with peripheral artery disease (PAD).

69 long-term diabetes complications, including peripheral artery disease (PAD).

70 ngiogenic cytokine elevated in patients with peripheral artery disease (PAD).

71 ood pressure (BP) response is exaggerated in peripheral artery disease (PAD).

72 ng is recognized as a strong risk factor for peripheral artery disease (PAD).

73 gerated exercise pressor reflex in rats with peripheral artery disease (PAD).

74 ng ischemia and tissue loss in patients with peripheral artery disease (PAD).

75 l infarction (MI), ischemic stroke (IS), and peripheral artery disease (PAD).

76 ve pulmonary disease (COPD; P=9.3 x 10(-4)), peripheral artery disease (PAD; P=0.090) and abdominal a

77 ), chronic kidney disease 4.4 (4.3-4.6), and peripheral artery disease 6.9 (6.8-7.0).

78 f Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424).

79 Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).

80 was consistently associated with stroke and peripheral artery disease across the different analyses.

81 es were measured in 226 patients with stable peripheral artery disease admitted for nonurgent invasiv

82 Peripheral artery disease affects >200 million people wo

83 Atherosclerotic peripheral artery disease affects 8% to 12% of Americans

84 Rivaroxaban in peripheral artery disease after revascularization.

85 % CI, 3.0-4.6) increased risk of amputation; peripheral artery disease alone conferred a 13.9-fold (9

86 le disparities in stroke, heart failure, and peripheral artery disease among African Americans.

87 g, adjusted HR 5.76 [4.90-6.77] for incident peripheral artery disease and 10.61 [5.70-19.77] for amp

88 ents with chronic coronary artery disease or peripheral artery disease and a history of mild or moder

89 rterial studies investigated lower-extremity peripheral artery disease and acute stroke (35% and 24%,

90 nd organizations to advance the treatment of peripheral artery disease and critical limb ischemia.

91 ents with chronic coronary artery disease or peripheral artery disease and history of heart failure (

92 NPR-C as an innovative approach to treating peripheral artery disease and ischemic cardiovascular di

93 d risk of amputation; and the combination of peripheral artery disease and microvascular disease was

94 to ischemic cardiovascular events, including peripheral artery disease and myocardial infarction, whi

95 om classification over time in patients with peripheral artery disease and the association of changes

96 enase bright (ALDHbr) cells in patients with peripheral artery disease and to explore associated clau

97 nd limb outcomes after revascularization for peripheral artery disease and, in particular, prognosis

98 neuroischaemic if peripheral neuropathy and peripheral artery disease are both present.

99 ents, we analysed adult participants without peripheral artery disease at baseline at the individual

100 sed 817 084 individuals without a history of peripheral artery disease at baseline from 21 cohorts.

101 professionals and millions of patients with peripheral artery disease at the 2015 Centers for Medica

102 anisms underlying the exercise impairment in peripheral artery disease based on an evaluation of the

103 atment of diabetic microvascular disease and peripheral artery disease but are hindered by the comple

104 The Western Pacific Region had the most peripheral artery disease cases (74.08 million), whereas

105 More than two thirds of the global peripheral artery disease cases were concentrated in 15

106 Future peripheral artery disease cell therapy investigational t

107 Conclusions and Relevance: Peripheral artery disease confers a poor prognosis in pa

108 The percutaneous therapies for peripheral artery disease continue to evolve with longer

109 Percutaneous therapies for peripheral artery disease continue to evolve with new te

110 Peripheral artery disease continues to become an increas

111 red and fifty-five patients with symptomatic peripheral artery disease due to de novo superficial fem

112 ith chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult part

113 May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres.

114 mates of the prevalence and risk factors for peripheral artery disease globally and regionally and, f

115 ificantly improved stratification of AAA and peripheral artery disease groups when compared with trad

116 lled based on previous revascularization for peripheral artery disease had higher rates of myocardial

117 Peripheral artery disease had to be defined as an ankle-

118 In the 21st century, peripheral artery disease has become a global problem.

119 lar procedures and bleeding in patients with peripheral artery disease has not been well described in

120 Patients with peripheral artery disease have a high risk of future car

121 Patients with peripheral artery disease have a marked reduction in exe

122 Patients with peripheral artery disease have an increased risk of card

123 the past decade, new epidemiological data on peripheral artery disease have emerged, enabling us to p

124 lobally, 202 million people were living with peripheral artery disease in 2010, 69.7% of them in LMIC

125 ple aged 25 years and older were living with peripheral artery disease in 2015, among whom 72.91% wer

126 pool the odds ratios of 30 risk factors for peripheral artery disease in HICs and LMICs.

127 Overall, the global prevalence of peripheral artery disease in people aged 25 years and ol

128 umber of recommendations for lower extremity peripheral artery disease in the current guideline, decr

129 h for studies reporting on the prevalence of peripheral artery disease in the general population that

130 3.05 ([95% CI, 1.92-4.85] P=2.30x10(-6)) for peripheral artery disease in the inverse variance-weight

131 There are >12 million patients with peripheral artery disease in the United States.

132 Treatment for symptomatic peripheral artery disease includes lower extremity bypas

133 ceding decade the number of individuals with peripheral artery disease increased by 28.7% in LMIC and

134 The prevalence of peripheral artery disease increased consistently with ag

135 Peripheral artery disease is a major cardiovascular dise

136 Lower limb peripheral artery disease is a prevalent chronic non-com

137 Peripheral artery disease is common and associated with

138 oral and popliteal arteries in patients with peripheral artery disease is compromised by restenosis a

139 Peripheral artery disease is considered to be a manifest

140 The most severe form of peripheral artery disease is critical limb ischemia (CLI

141 ents demonstrated among patients with stable peripheral artery disease is elevated after revasculariz

142 n important risk factors, a larger burden of peripheral artery disease is to be expected in the fores

143 thelial dysfunction present in patients with peripheral artery disease may be better understood by me

144 luting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery

145 Eligible patients had a history of peripheral artery disease of the lower extremities (prev

146 balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial femoral and

147 mia-reperfusion paradigm in 96 patients with peripheral artery disease of varying severity and 10 hea

148 with established coronary artery disease or peripheral artery disease often have diabetes mellitus.

149 regional and national numbers of people with peripheral artery disease on the basis of a risk factor-

150 justed analyses, compared with those without peripheral artery disease or microvascular disease, micr

151 myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb

152 ion, and lower ankle-brachial index identify peripheral artery disease patients at heightened risk fo

153 Revascularized peripheral artery disease patients face earlier limb and

154 vascularization and amputation procedures in peripheral artery disease patients.

155 inergic signaling plays an important role in peripheral artery disease progression.

156 this randomized trial in which patients with peripheral artery disease received treatment with paclit

157 s without subsequent ST in the Excellence in Peripheral Artery Disease registry.

158 anism of adverse limb events associated with peripheral artery disease remains incompletely understoo

159 Peripheral artery disease results in atherosclerotic obs

160 data to support use of these therapies after peripheral artery disease revascularization exist, and m

161 Both eGFR and ACR significantly improved peripheral artery disease risk discrimination beyond tra

162 luminal balloon angioplasty in patients with peripheral artery disease Rutherford-Becker class 2 to 5

163 induced ischemia are highly correlated with peripheral artery disease severity.

164 etinopathy, neuropathy, and nephropathy) and peripheral artery disease status on the risk of incident

165 l Artery Disease Study of 2013 and the China Peripheral Artery Disease Study as sources.

166 We also included the Global Peripheral Artery Disease Study of 2013 and the China Pe

167 tention should be paid to the development of peripheral artery disease symptoms and signs in people w

168 Critical limb ischemia is a manifestation of peripheral artery disease that carries significant morta

169 ed trial of 13 885 patients with symptomatic peripheral artery disease that tested the efficacy and s

170 d clinical trial that assigned patients with peripheral artery disease to clopidogrel or ticagrelor.

171 associated with 15 putative risk factors for peripheral artery disease to estimate their effect size

172 ly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ti

173 ants with chronic coronary artery disease or peripheral artery disease to rivaroxaban 2.5 mg twice da

174 ral Artery Disease) randomized patients with peripheral artery disease to ticagrelor versus clopidogr

175 elor In PAD) randomized 13 885 patients with peripheral artery disease to treatment with ticagrelor 9

176 ed increased late mortality in patients with peripheral artery disease treated with PTXDs.

177 Evidence from large, randomized, controlled peripheral artery disease trials reporting long-term out

178 trial enrolled 264 patients with symptomatic peripheral artery disease undergoing percutaneous treatm

179 ard ratios (HRs) for incident study-specific peripheral artery disease was 1.22 (95% CI 1.14-1.30) at

180 the adjusted HR for incident study-specific peripheral artery disease was 1.50 (1.41-1.59) at an ACR

181 Age-specific and sex-specific prevalence of peripheral artery disease was estimated in both high-inc

182 story of stroke, coronary artery disease, or peripheral artery disease were enrolled in a case-contro

183 patients with claudication and infrainguinal peripheral artery disease were randomized at 9 sites, of

184 butable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:

185 18 261 cases of peripheral artery disease were recorded during follow-up

186 ients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospital

187 In patients with peripheral artery disease who had undergone lower-extrem

188 In a double-blind trial, patients with peripheral artery disease who had undergone revasculariz

189 Patients with peripheral artery disease who have undergone lower-extre

190 th lower extremity ulcers and a diagnosis of peripheral artery disease who underwent a revascularizat

191 In patients with symptomatic peripheral artery disease with a history of limb revascu

192 uality of life for symptomatic patients with peripheral artery disease with intermittent claudication

193 The treatment of peripheral artery disease with percutaneous transluminal

194 EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) aimed to describe the inciden

195 ilure, valvular disease, venous disease, and peripheral artery disease) and the associated outcomes (

196 cular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated superiority of r

197 ID trial (Examining the Use of Ticagrelor in Peripheral Artery Disease) included 13 885 participants

198 ry heart disease, stroke, heart failure, and peripheral artery disease) occurred (236 events in subje

199 EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) population, subcategorize amp

200 EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) randomized patients with peri

201 EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) was a randomized clinical tri

202 tent claudication with objective evidence of peripheral artery disease), of the carotid arteries (pre

203 EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease), we examined the changes in R

204 disease, ischemic stroke, heart failure, and peripheral artery disease).

205 therothrombosis in patients with coronary or peripheral artery disease, and (4) the development of in

206 pment of HF, ischemic heart disease, stroke, peripheral artery disease, and chronic kidney disease.

207 onary heart disease, cerebrovascular events, peripheral artery disease, and congestive heart failure.

208 ia for up to 24 hours in the murine model of peripheral artery disease, and doubled muscle perfusion

209 of 5 patients with coronary artery disease, peripheral artery disease, and heart failure.

210 n off-loading, stimulation of wound healing, peripheral artery disease, and infection.

211 b has been shown to decrease angiogenesis in peripheral artery disease, and macrophages were well kno

212 G1/G2 alleles with coronary artery disease, peripheral artery disease, and stroke among black indivi

213 ation, atrial fibrillation, ischemic stroke, peripheral artery disease, and venous thromboembolism.

214 rce, heart failure, coronary artery disease, peripheral artery disease, antiphospholipid syndrome, an

215 s associated dose-dependently with CAD risk, peripheral artery disease, aortic valve stenosis, heart

216 , such as myocardial infarction, stroke, and peripheral artery disease, are the leading cause of morb

217 her heart rate, prior myocardial infarction, peripheral artery disease, Asian race, male sex, and hig

218 ischemia (CLI) is the most advanced stage of peripheral artery disease, associated with significant r

219 Older age, shorter height, ischemic cause, peripheral artery disease, atrial fibrillation, diabetes

220 ascularization of femoropopliteal lesions in peripheral artery disease, but mortality is a safety con

221 lure (HF), atrial fibrillation (AF), stroke, peripheral artery disease, cancer, liver-, rheumatic-, a

222 emoral artery of a rat for 72 h, a model for peripheral artery disease, causes an exaggerated exercis

223 Peripheral artery disease, common in metabolic syndrome

224 chronic lung disease, age 75 years or older, peripheral artery disease, diabetes, tobacco use, white

225 diagnoses (coronary artery disease, stroke, peripheral artery disease, dysrhythmias, or heart failur

226 cluding acute myocardial infarction, stroke, peripheral artery disease, heart failure and sudden card

227 In patients with symptomatic peripheral artery disease, in comparison with LEB, PVI w

228 ncluding hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, le

229 mb ischemia (CLI), the most advanced form of peripheral artery disease, is associated with significan

230 tical limb ischemia, the most severe form of peripheral artery disease, leads to extensive damage and

231 Among patients with symptomatic peripheral artery disease, noncardiovascular causes of d

232 ary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysm

233 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

234 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

235 nary artery diseases, heart failure, stroke, peripheral artery disease, or CVD-related mortality.

236 ng patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal ang

237 o be older, female, and have higher rates of peripheral artery disease, prior stroke, and hypertensio

238 In patients with coronary or peripheral artery disease, the combination of rivaroxaba

239 lasty (PTA) in patients with femoropopliteal peripheral artery disease, the long-term durability of D

240 In patients with symptomatic peripheral artery disease, ticagrelor was not shown to b

241 gina, stroke, transient ischemic attack, and peripheral artery disease, were adjudicated by committee

242 disease conferred increased risk of incident peripheral artery disease, with a strong association bet

243 ing 27,395 patients with chronic coronary or peripheral artery disease.

244 tions and many strokes, as well as disabling peripheral artery disease.

245 cholesterolaemia were major risk factors for peripheral artery disease.

246 nd localization in tissue from patients with peripheral artery disease.

247 ergistically increases risk in patients with peripheral artery disease.

248 ediated gene expression in a murine model of peripheral artery disease.

249 eGFR] and albuminuria) with the incidence of peripheral artery disease.

250 disease is a risk factor for lower-extremity peripheral artery disease.

251 potent antiplatelet agent, in patients with peripheral artery disease.

252 t advance in the management of patients with peripheral artery disease.

253 dependently associated with the incidence of peripheral artery disease.

254 artery is common in patients suffering from peripheral artery disease.

255 ction seen in rats with ligated arteries and peripheral artery disease.

256 etailing causes of death among patients with peripheral artery disease.

257 in patients with symptomatic femoropopliteal peripheral artery disease.

258 artery disease, cerebrovascular disease and peripheral artery disease.

259 as nonhealing ulcers or gangrene, related to peripheral artery disease.

260 in skeletal muscle biopsies from humans with peripheral artery disease.

261 y from chronic hindlimb ischemia, a model of peripheral artery disease.

262 he most common presentation of infrainguinal peripheral artery disease.

263 ergic signaling in a cohort of patients with peripheral artery disease.

264 in improving the outcomes for patients with peripheral artery disease.

265 of patients with symptomatic femoropopliteal peripheral artery disease.

266 pliteal lesions in symptomatic patients with peripheral artery disease.

267 athophysiology of the exercise impairment in peripheral artery disease.

268 l tool to investigate the pathophysiology of peripheral artery disease.

269 161 patients with AAA and 168 controls with peripheral artery disease.

270 low in the murine hindlimb ischemia model of peripheral artery disease.

271 to be underused among Medicare patients with peripheral artery disease.

272 consumption and increased risk of stroke and peripheral artery disease.

273 b endovascular interventions for symptomatic peripheral artery disease.

274 her hazard for MACE or MALE in patients with peripheral artery disease.

275 low blood pressure targets in patients with peripheral artery disease.

276 risk of amputation alone and in concert with peripheral artery disease.

277 gulant therapy in patients with coronary and peripheral artery disease.

278 uable tool for the treatment of coronary and peripheral artery disease; however, no solution is avail

279 rdial infarction, or stroke in patients with peripheral artery disease; however, vorapaxar significan

280 ncluded 13 885 participants with symptomatic peripheral artery disease; median follow-up was 30 month

281 d that greater large artery stiffness causes peripheral artery dysfunction; however, a cause-and-effe

282 ath, stroke, myocardial infarction, or acute peripheral artery emboli, were determined as well as maj

283 ncreased large artery stiffness and impaired peripheral artery function.

284 e and exercise performance in a rat model of peripheral artery insufficiency.

285 pacity in healthy rats and in a rat model of peripheral artery insufficiency.

286 (ST), which is a serious adverse outcome of peripheral artery interventions.

287 e about monocytes and their heterogeneity in peripheral artery occlusive disease (PAOD) still is limi

288 However, the effect of ischemic lower limb peripheral arteries on hemodynamics remains unclear.

289 polyvascular disease in 2 beds (coronary and peripheral artery or cerebrovascular), and 149 had polyv

290 on, but these changes are less pronounced in peripheral arteries, resulting in stiffness and geometry

291 confidence interval, 0.39-0.86; P=0.006) and peripheral artery revascularization (18.4% versus 22.2%;

292 Patients undergoing peripheral artery revascularization between January 1, 2

293 Management of peripheral artery stenosis and occlusion with vascular s

294 and NO bioavailability, was evaluated using peripheral artery tonometry (EndoPAT), and plasma levels

295 ve amplitude was continuously measured using peripheral artery tonometry (PAT, Itamar Inc).

296 (SDF) and endothelial function testing using peripheral artery tonometry are being performed at enrol

297 d NO-dependent endothelial function by using peripheral artery tonometry to determine the reactive hy

298 mmatory markers, vascular function (by using peripheral artery tonometry), and numbers of circulating

299 re on arterial volume distensibility between peripheral arteries with different compliance.

300 on intraluminal paclitaxel delivery to human peripheral arteries with substantial calcified plaque.